Evolv Technologies Holdings, Inc. filings document the public-company disclosures of an AI-based security screening business with Class A common stock and warrants listed on Nasdaq. Its Form 8-K reports include financial-results releases, Regulation FD disclosures, board and officer changes, stockholder meeting results, credit-agreement disclosures and registration-statement amendments tied to resale securities and warrant exercises.
Proxy materials describe director elections, executive compensation, auditor ratification, board committee matters and shareholder voting procedures. The filings also identify capital-structure elements, including Class A common stock, warrants and subsidiary borrowing arrangements, alongside governance and reporting matters for Evolv’s screening technology operations.
Evolv Technologies (EVLV) reported a quarter marked by accounting restatements, ongoing legal and regulatory matters, and continued operating losses despite product launches and financing. The company restated prior-period condensed consolidated financial statements after an internal investigation found extra-contractual terms that affected revenue recognition and led to personnel changes. Evolv had $36.9 million in cash, cash equivalents, and marketable securities as of June 30, 2025, and expects that, together with expected cash from operations and borrowing availability under newly negotiated Senior Secured Credit Facilities, it has at least twelve months of liquidity. The company recorded a net loss of $42.2 million for the six months ended June 30, 2025, recognized restructuring charges related to a reduction in force, and disclosed material weaknesses in internal controls with an active remediation plan. Significant contingencies include shareholder class and derivative actions, FTC and SEC matters, and an estimated $15.0 million settlement accrual for the class action with an expected $14.0 million insurance recovery.
Evolv Technologies Holdings, Inc. filed a current report describing two developments. The company announced that it released its financial results for the fiscal quarter ended June 30, 2025, with the full details provided in a separate press release furnished as an exhibit.
The company also reported that Michael Ellenbogen, its Chief Innovation Officer and a member of the Board of Directors, informed the company on August 13, 2025 that he will resign from his Chief Innovation Officer role effective September 5, 2025, citing new time commitments. His decision is stated to be not due to any disagreements with the company. He will continue to serve as a member of the Board and will receive compensation as a non-employee director under the company’s director compensation policy.
Michael Ellenbogen, Founder & Chief Innovation Officer and Director of Evolv Technologies Holdings, reported significant changes in beneficial ownership on June 23, 2025. The key transaction involved the transfer of investment control of 2,259,987 shares of Class A Common Stock previously held by E Ventures Trust to an independent investment advisor.
Following this transaction, Ellenbogen's holdings include:
- 2,083,961 shares held directly
- 151,135 shares held indirectly through Family Horizon Trust
The transfer of investment control means Ellenbogen no longer has beneficial ownership of the E Ventures Trust shares and will not include them in future Section 16 reports. This represents a significant change in his control over company shares while maintaining his executive and board positions.
Evolv Technologies Holdings (NASDAQ: EVLV) filed a Form 4 detailing routine equity movements by director Richard A. Shapiro. On June 19 2025 he acquired 12,515 Class A shares at $0 when a prior restricted stock unit (RSU) award vested. A day later, on June 20 2025, he received a new grant of 27,050 RSUs that will vest in full on the earlier of June 20 2026 or the day before the next annual meeting. Following these transactions Shapiro now holds 22,515 shares directly, plus indirect interests—30,000 shares held by his spouse, 15,000 in a trust, and 7,600 in a spouse retirement plan—for a combined indirect total of 52,600 shares. No shares were sold, and the transactions represent standard non-employee director compensation rather than open-market purchases or sales.
Evolv Technologies (NASDAQ:EVLV) filed a routine Form 4 disclosing an equity award to director Neil Glat. On June 20, 2025, Glat received 27,050 Restricted Stock Units (RSUs), each representing one share of Class A common stock. The RSUs carry no exercise price and will vest in full on the earlier of June 20, 2026 or the day immediately preceding the company’s next annual meeting. Following the grant, Glat beneficially owns 27,050 shares directly. No sales, dispositions, or other material transactions were reported.